Scarica l'app Stockscreener
31.26
2.26%
0.69
Pre-mercato:
30.75
-0.51
-1.63%
Precedente Chiudi:
$30.57
Aprire:
$30.78
Volume 24 ore:
937.74K
Relative Volume:
0.76
Capitalizzazione di mercato:
$2.96B
Reddito:
$225.27M
Utile/perdita netta:
$-140.06M
Rapporto P/E:
-19.57
EPS:
-1.5974
Flusso di cassa netto:
$-87.93M
1 W Prestazione:
+13.26%
1M Prestazione:
+10.81%
6M Prestazione:
-7.32%
1 anno Prestazione:
+42.61%
Intervallo 1D:
$30.45
$31.70
Intervallo di 1 settimana:
$27.36
$31.70
Portata 52W:
$20.50
$39.28
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Nome
Ideaya Biosciences Inc
Settore
Industria
Telefono
650-443-6209
Indirizzo
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
31.26 | 2.86B | 225.27M | -140.06M | -87.93M | -1.5974 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-09-18 | Iniziato | Guggenheim | Buy |
| 2025-09-04 | Iniziato | Barclays | Overweight |
| 2025-09-04 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-07-22 | Iniziato | TD Cowen | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-06-26 | Iniziato | Wells Fargo | Overweight |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-11-05 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2024-03-08 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Outperform |
| 2023-05-24 | Iniziato | Goldman | Buy |
| 2023-04-24 | Aggiornamento | Stifel | Hold → Buy |
| 2023-03-23 | Iniziato | Berenberg | Buy |
| 2023-02-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-12-28 | Iniziato | CapitalOne | Overweight |
| 2022-10-27 | Iniziato | Citigroup | Buy |
| 2022-08-15 | Downgrade | Stifel | Buy → Hold |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-10 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-11 | Iniziato | Guggenheim | Buy |
| 2020-10-07 | Iniziato | Wedbush | Outperform |
| 2020-09-01 | Iniziato | Northland Capital | Outperform |
| 2020-07-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-06 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-13 | Iniziato | ROTH Capital | Buy |
| 2019-10-17 | Iniziato | Oppenheimer | Outperform |
| 2019-09-10 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-17 | Iniziato | Citigroup | Buy |
| 2019-06-17 | Iniziato | JP Morgan | Neutral |
| 2019-06-17 | Iniziato | Jefferies | Buy |
Mostra tutto
Ideaya Biosciences Inc Borsa (IDYA) Ultime notizie
Responsive Playbooks and the IDYA Inflection - Stock Traders Daily
IDEAYA Biosciences enrolls first patient in IDE892 Phase 1/2 trial - grafa.com
Why is Ideaya Biosciences stock rallying today? By Investing.com - Investing.com Canada
Ideaya Biosciences stock rises on phase 1/2 cancer trial start By Investing.com - Investing.com South Africa
Ideaya begins trial of IDE892 combo in lung, pancreatic cancer - Investing.com
IDEAYA Biosciences, Inc. (IDYA) Latest Stock News & Headlines - Yahoo Finance
New drug combo targets MTAP-deleted pancreatic and lung cancers - Stock Titan
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
Wedbush Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58 - Moomoo
IDEAYA Biosciences, Inc. (IDYA) reports Q1 loss, misses revenue estimates - MSN
IDEAYA files shelf offering to raise up to $300M - MSN
Ideaya Biosciences (IDYA) Forms Clinical Partnership With Roche for IDE892 Efficacy Study - Insider Monkey
IDEAYA Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion H2 2026 - Seeking Alpha
Ideaya Biosciences Stock Crashes 10% Despite Citizens Reiterating Highly Bullish Price Target on Oncology Pipeline - TIKR.com
IDEAYA Biosciences prices $300M public offering of shares and pre-funded warrants at $27/share - MSN
IDEAYA Announces Closing of Public Offering Including Full Exerc - GuruFocus
IDEAYA Biosciences closes $345M public offering By Investing.com - Investing.com South Africa
IDEAYA Biosciences closes $345M public offering - Investing.com
IDEAYA Biosciences raises $323.6M in follow-on offering of common stock and pre-funded warrants - TradingView
IDEAYA Biosciences (NASDAQ: IDYA) raises $323.6M via stock and pre-funded warrants - Stock Titan
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PR Newswire
5 Best AI Driven Biotech Stocks to Invest In - Insider Monkey
IDEAYA (NASDAQ: IDYA) raises ~$281M via 5.56M shares and pre-funded warrants - Stock Titan
UBS Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Update: IDEAYA Shares Fall After Pricing $300 Million Offering - Moomoo
Peninsula company lines up $345 million stock deal targeting eye cancer - The Business Journals
Mission Produce Posts Downbeat Q2 Earnings, Joins Ideaya Biosciences, Perrigo And Other Big Stocks Moving - Benzinga
Ideaya: Expect Offering to Close on or About June 10 >IDYA - Moomoo
Citizens reiterates Ideaya Biosciences stock rating on ASCO data By Investing.com - Investing.com Canada
IDEAYA Biosciences prices $300 million stock offering By Investing.com - Investing.com Australia
IDEAYA Biosciences prices $300 million stock offering - Investing.com UK
IDEAYA sets $27 price in $300M stock and warrant sale to investors - Stock Titan
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants - Financial Times
IDEAYA Announces Proposed Public Offering of Common Stock and Pr - GuruFocus
Ideaya Biosciences stock falls on $300M stock offering plan By Investing.com - Investing.com Australia
IDEAYA Biosciences plans $300 million stock offering By Investing.com - Investing.com Australia
Ideaya Biosciences stock falls on $300M stock offering plan - Investing.com India
IDEAYA Biosciences plans $300 million stock offering - Investing.com
IDEAYA (NASDAQ: IDYA) seeks $300M in stock and pre-funded warrants, $45M option - Stock Titan
IDEAYA Biosciences plans up to $300M stock, warrant sale, plus $45M option - Stock Titan
What IDEAYA Biosciences (IDYA)'s Darovasertib Phase 2/3 Win and Roche Deal Mean For Shareholders - Yahoo Finance
IDEAYA (IDYA) Chief Development Officer reports 297,200-share stock option holding - Stock Titan
Understanding the Setup: (IDYA) and Scalable Risk - Stock Traders Daily
Ideaya Biosciences Inc Azioni (IDYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):